
NanoViricides NNVC
€ 0.81
-3.18%
Quartalsbericht 2025-Q4
hinzugefügt 17.02.2026
NanoViricides Gesamtes Eigenkapital 2011-2026 | NNVC
Gesamtes Eigenkapital Jährlich NanoViricides
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.52 M | 11.5 M | 14.9 M | 23.1 M | 29.9 M | 21.8 M | 10.6 M | 17.7 M | 20.3 M | 23 M | 31.8 M | 23.4 M | 8.01 M | 13.9 M | 10.2 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 31.8 M | 7.52 M | 17.8 M |
Gesamtes Eigenkapital Vierteljährlich NanoViricides
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.1 M | 7.17 M | 7.52 M | 8.83 M | 10.4 M | 10.1 M | 11.5 M | 10.7 M | 12.5 M | 13 M | 14.9 M | 18.2 M | 19.9 M | 21.6 M | 23.1 M | 24.8 M | 26.5 M | 28.3 M | 29.9 M | 31.9 M | 27.7 M | 27.7 M | 27.7 M | 30 M | 7.72 M | 7.72 M | 7.72 M | 9.13 M | 13.8 M | 13.8 M | 13.8 M | 16 M | 15.9 M | 18.5 M | 15.9 M | 18.5 M | 19.1 M | 20.2 M | 23 M | 23 M | 28.4 M | 30.7 M | 31.8 M | 31.8 M | 30.5 M | 32.2 M | 23.4 M | 36.8 M | 7.1 M | 8.31 M | 10.2 M | 11.8 M | 14.2 M | 12.8 M | 13.9 M | 12.8 M | 12.4 M | 11.4 M | 10.2 M | 10.2 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 36.8 M | 7.1 M | 18 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
5.18 T | $ 18.06 | - | $ 28.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.44 | -0.46 % | $ 909 M | ||
|
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
Protara Therapeutics
TARA
|
196 M | $ 5.03 | -3.08 % | $ 215 M | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
Tarsus Pharmaceuticals
TARS
|
343 M | $ 67.0 | -0.3 % | $ 2.8 B | ||
|
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
Theravance Biopharma
TBPH
|
297 M | $ 14.9 | -1.91 % | $ 750 M | ||
|
Avid Bioservices
CDMO
|
60.9 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.2 | -6.97 % | $ 306 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
Bio-Techne Corporation
TECH
|
1.92 B | $ 51.31 | -2.65 % | $ 8.08 B | ||
|
Tenax Therapeutics
TENX
|
97.1 M | $ 14.64 | -2.2 % | $ 574 M | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
23.6 M | $ 1.07 | -2.29 % | $ 21.9 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
7.91 B | $ 28.76 | -3.43 % | $ 32.9 B | ||
|
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Equillium
EQ
|
28.6 M | $ 2.03 | -1.46 % | $ 116 M | ||
|
Eton Pharmaceuticals
ETON
|
26.2 M | $ 23.81 | 1.51 % | $ 641 M | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 46.38 | -2.45 % | $ 4.17 B |